BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Bortezomib

A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.

300+ PubMed studies analyzed · 9 RCTs · Evidence Score: 48.3

Research Domains

Bortezomib has been studied across 18 research domains including 🔬 Oncology, ⏳ Longevity & Aging, 🛡️ Immunity, ⚡ Energy & Fatigue, 🔬 Inflammation. The primary research focus is 🔬 Oncology with 56% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Bortezomib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Reserpine
37 shared targets
Daunorubicin
39 shared targets
Celecoxib
35 shared targets
cycloheximide
31 shared targets
Resveratrol
36 shared targets
Emetine
27 shared targets
Camptothecin
27 shared targets
Ethinyl
30 shared targets
Dactinomycin
25 shared targets
vinblastine
28 shared targets
Loading evidence profile...

This evidence profile for Bortezomib is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.